The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites

Hepatology

Volumn 23, Issue 5, 1996, Pages 1047-1052

  Nevens, Frederik ^a   Lijnen, Paul ^a   VanBilloen, Hubert ^a   Fevery, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; FUROSEMIDE; PLACEBO; PROPRANOLOL; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ESOPHAGUS PRESSURE; ESOPHAGUS VARICES BLEEDING; FEMALE; GYNECOMASTIA; HEMODYNAMIC PARAMETERS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PLASMA VOLUME; PORTAL HYPERTENSION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029869773     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v23.pm0008621132     Document Type: Article

References (23)

1. Nevens F, Broeckaert L, Rutgeerts P, Van Steenbergen W, Fevery J. The long-term morbidity and mortality rate in a cohort of patients with liver cirrhosis and oesophageal varices. Hepato-Gastroenterology 1995;42:979-984.
2. Lebrec D, Corbie M, Novel O, Benhamou JP. Propranolol, a medical treatment for portal hypertension? Lancet 1980;2:180-182.
3. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-1407.
4. Bosch J, García-Pagán JC, Feu F, Luca A, Fernández M, Pizcueta P, Rodés J, et al. New approaches in the pharmacologic treatment of portal hypertension. J Hepatol 1993;17(suppl 2): 41-45.
5. Zimmons DS, Kessler RE. The portal pressure blood volume relationship in cirrhosis. Gut 1974;15:99-101.
6. Okumura H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, Terada H, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.
7. Garcia-Pagan JC, Salméron JM, Feu F, Luca A, Ginés P, Pizcueta P, Clarice J, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. HEPATOLOGY 1994;19:1095-1099.
8. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986;6:318-331.
9. Bosch J, Bordas JM, Rigau J, Viola C, Mastai R, Kravetz D, Navasa M, et al. Noninvasive measurement of the pressure of esophageal varices using an endoscopie gauge: comparison with measurements by variceal puncture in patients undergoing endoscopie sclerotherapy. HEPATOLOGY 1986;6:667-672.
10. Nevens F, Sprengers D, Feu F, Bosch J, Fevery J. Measurement of variceal pressure with an endoscopie pressure sensitive gauge: validation and effect of propranolol therapy in chronic conditions. J Hepatol 1996;24:66-73.
11. Nevens F, Van Steenbergen W, Yap SH, Fevery J. Assessment of variceal pressure by continuous non-invasive endoscopie registration: a placebo-controlled evaluation of the effect of terlipressin and octreotide. Gut 1996;38:129-134.
12. Lijnen P, Fagard R, Staessen J, Amery A. Hormonal effects of the diuretic xipamide in healthy men. Cardiovascular Drugs and Therapy 1991;5:741-746.
13. Lijnen P, Hespel P, M'Buyamba-Kabangu JR, Goris M, Lysens R, Vanden Eynde E, Fagard R, et al. Plasma atrial natriuretic peptide and cyclic nucleotide levels before and after a marathon. J Appl Physiol 1987;63:1180-1184.
14. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D, et al. Beta-adrenergic-antagonistic drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med 1991;324:1532-1538.
15. Grace ND. Prevention of initial variceal hemorrhage in complications of portal hypertension: esophagogastric varices and ascites. Gastroenterol Clin N Am 1992;21:149-161.
16. Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986;90:1232-1240.
17. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. HEPATOLOGY 1992;15:323-328.
18. Rigau J, Bosch J, Bordas JM, Navasa M, Mastai R, Kravetz D, Bruix J, et al. Endoscopie measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage. Gastroenterology 1989;96:873-880.
19. Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, Rodés J. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. HEPATOLOGY 1984;4: 1200-1205.
20. Sogni P, Soupison T, Moreau R, Le Moine O, Bacq Y, Hadengue A, Lebrec D. Hemodynamic effects of acute administration of furosemide in patients with cirrhosis receiving ß-adrenergic antagonists. J Hepatol 1994;20:548-552.
21. Cereda J-M, Roulot D, Braillon A, Moreau R, Koshy A, Lebrec D. Reduction of portal pressure by acute administration of furosemide in patients with alcoholic cirrhosis. J Hepatol 1989;9:246-251.
22. Dacquct C, Loirand G, Mironneau C, Mironneau J, Pacaud P. Spironolactone inhibition of contraction and calcium channels in rat portal vein. Br J Pharmacol 1987;92:535-544.
23. The Italian Multicenter Project for Propranolol in Prevention of Bleeding. Propranolol for prophylaxis of bleeding in cirrhotic patients with large varices: a multicenter, randomized clinical trial. HEPATOLOGY 1988;8:1-5.